The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 15 of the 22 sources its claims cite were checked for support.
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial
Open accessAbstract
Background In the US Diabetes Prevention Program (DPP), a 3-year randomised clinical trial in 3234 adults with prediabetes, type 2 diabetes incidence was reduced by 58% with intensive lifestyle intervention (ILS) and by 31% with metformin, compared with placebo. We sought to assess the long-term effects and potential heterogeneity of treatment effects over approximately 21 years of follow-up. Methods The DPP trial was continued with protocol modifications as the DPP Outcomes Study (DPPOS). In the DPPOS, placebo was discontinued, metformin (850 mg twice a day as tolerated) was continued after unmasking, and group-based booster intervention classes were offered to the ILS group twice a year; additionally, all participants were offered group-based lifestyle intervention four times a year. The prespecified primary outcome during DPP and DPPOS was diabetes incidence defined by American Diabetes Association criteria. The DPPOS protocol specified continued diabetes incidence as an outcome; Feb 23, 2020, was chosen as the closing date for the present analysis, as a date prior to the COVID-19 pandemic, which caused major disruptions in clinic visits and complicated longitudinal data analyses. We assessed long-term persistence of intervention effects on diabetes incidence, and heterogeneity of effects in subgroups defined by baseline diabetes risk factors. Follow-up is reported for the combined study from July 31, 1996, to Feb 23, 2020, and analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, NCT00004992 (DPP) and NCT00038727 (DPPOS); follow-up is ongoing but the trial is closed to enrolment except for previous DPP participants. Findings 3195 participants originally enrolled in the DPP were included in the present analyses. This population comprised 2171 (67·9%) female participants and 1024 (32·1%) male participants, with a mean baseline age of 50·6 years (SD 10·7). Individual follow-up times ranged from 0·2 to 23·2 years (median 8·0 years [IQR 3·0 to 18·0]); remaining numbers at risk decreased sharply after 21 years because of administrative censoring and thus follow-up was considered to represent a 21-year period. During follow-up, compared with placebo, diabetes incidence rate was reduced in the original ILS group (hazard ratio [HR] 0·76 [95% CI 0·68 to 0·85], rate difference [RD] -1·59 cases [95% CI -2·25 to -0·93] per 100 person-years) and in the original metformin group (HR 0·83 [0·74 to 0·93], RD -1·17 [-1·85 to -0·49]), with corresponding increases in median diabetes-free survival of 3·5 years and 2·5 years, and mean diabetes-free survival of 2·0 years (95% CI 1·2 to 2·8) and 1·2 years (0·4 to 2·0), respectively. The diabetes cumulative incidence curves separated early, especially in the first 3 years, with lower incidence rates in the metformin and ILS groups than in the placebo group. The metformin and ILS curves progressively converged with longer follow-up. The overall treatment effects appeared to result from large early effects during the DPP. Absolute intervention effects, measured as RDs versus placebo, were greater with ILS in participants with higher values for baseline fasting glucose, HbA 1c, and multivariable clinical and physiological risk indices, and with metformin in younger participants. Interpretation The large initial intervention effects seen in the DPP trial were followed by sustained reductions in cumulative diabetes incidence for 21 years. Intervention effects were heterogeneous according to some baseline variables. These findings could guide precision interventions to help address the current type 2 diabetes epidemic. Funding US National Institute of Diabetes and Digestive and Kidney Diseases and other agencies. Translation For the Spanish translation of the abstract see Supplementary Materials section.
Overview
CoChat Summary
TL;DR
In the US Diabetes Prevention Program/DPPOS, intensive lifestyle and metformin interventions produced sustained reductions in type 2 diabetes incidence over about 22 years, largely due to large early effects that did not rebound. Effects were heterogeneous, with greater absolute benefit in higher-risk subgroups and little or no benefit in some lower-risk or older subgroups.
Key findings
- Over 22 years, compared with placebo, intensive lifestyle (ILS) reduced diabetes incidence by 24% (HR=0.76, 95% CI 0.68–0.85; rate difference [RD]=−1.59 [−2.25, −0.93] cases/100 person-years), and metformin reduced it by 17% (HR=0.83 [0.74, 0.93]; RD=−1.17 [−1.85, −0.49]).
- Median diabetes-free survival was delayed by 3.5 years with ILS and 2.5 years with metformin; mean diabetes-free survival increased by 2.0 [1.2, 2.8] and 1.2 [0.4, 2.0] years/person, respectively. At 21 years, cumulative incidence was 70% (67–73%) with placebo, 64% (61–68%) with metformin, and 66% (62–69%) with lifestyle.
- Absolute ILS effects were greater in subgroups with higher baseline fasting glucose, HbA1c, and multivariable clinical/physiologic risk indices; in the highest physiologic risk tertile, ILS RD was −5.77 cases/100 person-years versus −0.56 in the lowest tertile (interaction p<0.001).
- Metformin effects were heterogeneous by age on the absolute scale: RD was −2.21 cases/100 person-years in younger participants but +0.41 in older participants (p-heterogeneity=0.04). No significant treatment-by-subgroup interactions were found for sex, race/ethnicity, or baseline BMI.
Methods
- The Diabetes Prevention Program (DPP) randomized 3,234 adults with prediabetes to placebo, metformin, or ILS; 3,195 were included in these analyses. After DPP, the DPP Outcomes Study continued follow-up with placebo discontinued, metformin continued in the original metformin group, and group-based lifestyle offered to all; follow-up reported from 31 July 1996 to 23 February 2020 (mean 22 years).
- Intention-to-treat analyses compared metformin and ILS with placebo. Time to diabetes used modified product-limit life tables and log-rank tests; incidence rates were cases/100 person-years; rate differences used Poisson models; hazard ratios used proportional hazards regression.
- Heterogeneity was assessed by a priori baseline subgroups and by two multivariable risk indices (clinical and physiologic). Cumulative incidence was estimated by Kaplan-Meier curves, with median and restricted mean diabetes-free survival times.
Limitations
- The paper states that post-DPP protocol changes—unmasking, stopping placebo, continuing metformin in the original metformin group, and offering lifestyle coaching to all participants—make long-term ILS effects less clear to interpret.
- The paper states that generalizability is limited to persons meeting DPP eligibility criteria; whether results apply to broader prediabetes definitions is unknown, and diabetes was assessed systematically with oral glucose tolerance testing in the trial, whereas outside research settings assessment may be less frequent or accurate.
- The paper states that the multivariable risk indices were derived within the study and were not intended or validated for clinical use; hazard ratios were not always proportional over time and represent averages over follow-up. The text also makes evident that later follow-up comparisons reflect original randomization plus differential ongoing treatments and possible depletion of the most diabetes-susceptible participants.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 7 Not valid · 5 Not checked · 59 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In two more recent diabetes prevention clinical trials, interventions were less effective22 or equally effective23 in persons with isolated impaired fasting glucose compared with impaired glucose tolerance with or without impaired fasting glucose.”
§ Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial > DISCUSSION
What the sources say
- Could not verifycites [22] Lee, 2019, Number and characteristics of US adults meeting prediabetes criteria for diabetes prevention programs: NHANES 2007–2016, J Gen Intern Med sourceExperimental — accuracy not yet measured
The Results (pp. 1–2) compare the numbers and characteristics of US adults eligible for diabetes prevention programs, not intervention effectiveness in clinical trials. The Introduction (p. 1) says differences in eligibility criteria may influence effectiveness, but our copy does not compare outcomes for isolated impaired fasting glucose versus impaired glucose tolerance. Searches for that comparison and for reduced intervention effectiveness found no supporting passage. (LLM, conf=0.76)
- Disputedcites [23] Knowler, 2011, Prevention of type 2 diabetes: comment on “Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels”, Arch Intern Med sourceExperimental — accuracy not yet measured
The citation is attached to “equally effective,” but the paper’s discussion of the Japanese trial reports greater risk reduction in higher-risk subgroups, including those with impaired glucose tolerance, and no observed risk reduction in those with isolated impaired fasting glucose. It cautions that the estimate for the isolated-IFG group was very imprecise, so the finding does not establish how large the difference was. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Weight loss was a major contributor to the reduction in diabetes incidence in the ILS and metformin groups.17, 18”
§ Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial > DISCUSSION
What the sources say
- Partly supportedcites [17] Gong, 2019, Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study, Lancet Diabetes Endocrinol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that investigators in the Diabetes Prevention Program and Finnish Diabetes Prevention Study considered weight loss important in reducing diabetes incidence, supporting the lifestyle-intervention portion of the claim. It does not say weight loss was a major contributor in a metformin group; for the Da Qing intervention, it instead points mainly to dietary changes and physical activity rather than weight loss. (LLM, conf=0.88)
- Partly supportedcites [18] 2018, Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement, JAMA sourceExperimental — accuracy not yet measured
The Behavior-Based Weight Loss and Weight Loss Maintenance Interventions section (page unavailable) reports lower diabetes incidence and greater weight loss in behavioral intervention groups. It does not say that weight loss was a major contributor to the incidence reduction, or establish that relationship for the metformin group. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In Japan, a lifestyle intervention for diabetes prevention was effective in persons with impaired fasting glucose only if they had an additional risk factor such as elevated HbA1c or impaired glucose tolerance.21”
§ Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial > DISCUSSION
What the sources say
- Partly supportedcites [21] Lachin, 2007, Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program, Diabetes sourceExperimental — accuracy not yet measured
The introductory passage labeled Abstract (page unavailable) reports that lifestyle intervention reduced diabetes risk in the DPP, whose participants had elevated fasting glucose and impaired glucose tolerance. It does not report a Japanese intervention or compare people with impaired fasting glucose alone against those with additional risk factors, so it cannot support the claim that the intervention worked only in the latter group. (LLM, conf=0.78)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Although they may apply only to persons meeting the DPP eligibility criteria of BMI and fasting and 2-hour post-load glucose, DPP participants represent a substantial fraction of the US adult population.”
§ Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial > DISCUSSION
What the sources say
- Could not verifycites [19] Hamman, 2015, Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS), Diabetes sourceExperimental — accuracy not yet measured
The Participants section (page unavailable) describes the DPP eligibility criteria and enrollment, but does not estimate how many US adults met those criteria. Searches for a substantial fraction of the US adult population and for population prevalence or generalizability found no passage addressing the claimed fraction. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment effects on median diabetes-free times are generally greater than effects on mean times (Table 1, Appendix p. 12–14).”
§ Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial > DISCUSSION
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
30 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 9
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial > RESULTS
“As a percentage of time in the study, the maximal intervention benefit of ILS occurred at about six years after randomization, and the benefit continued to increase gradually for metformin after six years (Appendix p. 7, panel D).”
§ Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial > DISCUSSION
“As a percentage of follow-up time, the extra diabetes-free survival time peaked at about six years for ILS and plateaued after six years in the metformin group.”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Self-citationDiabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Effect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Self-citationRoyston, P., & Parmar, M. K. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-152 · Cited by 1,062
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Ratner, R. E., Christophi, C. A., Metzger, B. E., Dabelea, D., Bennett, P. H., Pi-Sunyer, X., Fowler, S., Kahn, S. E., & The Diabetes Prevention Program Research Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0772 · Cited by 867
Self-citation(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Cited by
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s003 · Cited by 103
Self-citationChen, M., Guo, J., Shangguan, Y., Sun, Z., He, X., Tu, Q., & Yan, Q. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02921-3 · Cited by 45
“…Mediterranean dietary patterns [75, 76], structured aerobic–resistance exercise [77, 78], smoking cessation [79], and intensive lifestyle programs [80]—and pharmacological interventions including GLP-1 receptor agonists [81], SGLT2 inhibitors [82], and statins can meaningfully reduce central…”
Beyond Glucose—Rethinking Prediabetes for Precision Prevention
Wagner, R. J., Selvin, E., Sehgal, R., Prystupa, K., Misra, S., Fritsche, A., & Heni, M. (2025) · Diabetes Care · doi:10.2337/dci25-0054 · Cited by 28
Dagogo-Jack, S. E. (2025) · Diabetes · doi:10.2337/dbi25-0006 · Cited by 25
Self-citationLifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes
Salive, M. E., Tjaden, A. H., Ames, J. R., Crandall, J. P., Dabelea, D., Hazuda, H. P., Heckman‐Stoddard, B. M., Huckfeldt, P. J., Kuo, S., Strotmeyer, E. S., et al. (2026) · JAMA · doi:10.1001/jama.2026.8492 · Cited by 7
Self-citation
Metadata
- Authors
- Knowler, W. C., Doherty, L., Edelstein, S. L., Bennett, P. H., Dabelea, D., Hoskin, M., Kahn, S. E., Kalyani, R. R., Kim, C., Pi-Sunyer, F. X., Raghavan, S., Shah, V. O., Temprosa, M., Venditti, E. M., Nathan, D. M., Abbas, C., Abbott, K., Abebe, S., Ackermann, R. T., Acton, K. J., Adams, K. S., Adelman, D. T., Adorno, E., Agharanya, N., Akbar, K., Albers, J., Aldrich, F. A., Alexander, T., Allen, A., Allison, D. B., Altshuler, D., Anderson, D. R., Anderson, E., Anderson, H., Andon, N., Andre, V. L., Applegate, W. B., Arakaki, R. F., Arceneaux, J., Arky, R. A., Aroda, V., Aronoff, N. J., Atler, L. F., Bain, R., Baker-Ladao, N. K., Baldo, M., Ballonoff, L. B., Bamdad, J., Barber, R., Barkalow, M., Barr, S., Barrett, N., Barrett-Connor, E., Bassiouni, S., Baumhauer, H., Bavido-Arrage, C., Beddow, R., Begay, S., Behrends, C., Beltran, M., Benchoff, C., Bennett, P. H., Benson, M., Benz, W., Bermudez, N. E., Bethepu, J., Bezabeh, T., Billings, L. K., Bird, E. C., Bissett, L., Blodi, B., Boggs, G., Bondi, K., Boraz, M., Botrous, M., Bouffard, A., Bowers, A., Boyle, P. J., Bradley, V., Brancati, F. L., Brändle, M., Bray, G. A., Brenneman, T., Bronsord, M., Broussard, B. A., Brown, E., Brown, A., Brown, A. L., Brown, J. O., Brown, M. B., Bryant, M., Bryer-Ash, M., Bucca, B. C., Budget, M., Budoff, M., Burge, M. R., Burke, J. P., Butler, N., Caballero, E., Cagliero, E., Callaghan, J., Callaphan, K. M., Calles, J., Calonge, B. N., Campbell, C., Canady, J. L., Cantrell, C. M., Cappelli, S., Caro, J. F., Carrion-Petersen, M., Carter, C. E., Casillas, A., Cassanova-Romero, P., Castillo-Florez, S., Chai, L., Champagne, C. M., Chan, M., Charleston, J. B., Chatellier, A., Chavez, M., Cheatham, W. W., Chen, L., Chong, H., Christophi, C., Chu, K., Claravall, L. N., Clark, B., Clark, D., Clark, J. M., Clifford, L., Cohn, H., Cola, S., Colegrove, C., Colleran, K., Conzues, C., Cooeyate, N., Cook, S., Cook, M., Corkery, E., Cox, L., Crandall, J. P., Culbert, I. W., Culyba, R., Curtis, J., Czech, K., D'Anna, K., Dabelea, D., Dacawyma, T., Dagogo-Jack, S., Dailing, C., Danis, R., Darwin, C., Das, S., David, K., Davis, M., deGroot, M., Delahanty, L., Delve, L., DeSandre, C., Dias, L., Dodge, C., Doherty, L., Dohm, K., Dolgoff, J., Domalpally, A., Donahue, R. P., Dotson, B., Dotson, Y. F., Doughty, M. S., Dowden, J. M., Dragg, A., Duffy, H., Duncan, C., Duncan, R., Dwyer, G. M., Eastman, R., Eberhardt, B., Edelman, S. V., Edelstein, S. L., Edgerton, C., Ehrmann, D. A., Elsas, D., Endres, R., Engel, S., Enote, A., Evans, C., Evans, G., Ewen, A., Farago, M., Fargnoli, B., Fattaleh, B., Fineberg, E. S., Fisher, E., Fitzgibbon, M., Florez, H. J., Florez, J. C., Fondino, A., Foo, S. T., Foulkes, M., Fowler, S., Fradkin, J., Franklin, T., Franks, P. W., Frazier, M., Freel, J., Friedler, A., Frieson, S. L., Fujimoto, W., Fultz, M., Furlong, K., Gabrielson, D., Gadde, K. M., Gama, V., Ganda, O. P., Ganiats, T., Gao, Y., Garfield, S., Garg, R., Garimella, P., Ghahate, J. M., Giannella, A., Gibbs, P., Giles, M. M., Gilligan, R., Gillis, B., Glass, J., Glass, M., Gohdes, D., Goldberg, R. B., Goldman, V., Goldstein, B. J., Goldstein, A., Gonzales, Y., Gooding, R., Gottlieb, A., Goulding, A., Grant, W., Grassa, E., Greene, A., Greenway, F., Gregg, E., Grimes, K. L., Groessl, E., Grover-Fairchild, N., Guare, J. C., Guidi, A., Guido, M., Guillory, F. G., Guimond, S., Gurry, L., Hadden, A., Haffner, S. M., Haffner, L., Hagamen, S., Hall, S., Hamman, R. F., Hampton, E. F., Hanson, R. L., Harden, M., Harrier, S., Harris, L., Harting, J., Hartmuller, M., Hattaway, K., Hazuda, H. P., Heard, D., Hemphill, C., Henry, R. R., Hensley, S., Herbert, A. A., Herman, W. H., Hernandez-McGinnis, D. A., Hilbrich, R., Hill, J. O., Hill Golden, S., Hivert, M.-F., Hoffman, H., Hogan Tjaden, A., Horak, K., Horne, J., Horse, E., Horton, E. S., Horwich, T., Hoskin, M. A., Howard-Century, C. J., Hoyer, S. R., Hu, J., Hubbard, L., Hurt, E., Hurtenbach, C., Hyde, P., Ibebuogu, U., Ignaut, J. M., Imseis, R., Ingraham, L. E., Inouye, J., Isaac, J., Isonaga, M. K., Jablonski, K., Jackson, M., Jackson, M. A., Jackson, S. D., Jacobsen, A. M., Janicek, R., Jay, P., Jeffirs, M. L., Jeffries, S., Jenkins, T., Jiggetts, D., Jinagouda, S., Johannes, C., Johnson, D., Johnson, M. K., Johnson, C. K. H., Johnson, S., Jones, S., Jones, T. L., Jones, T., Jortberg, B. T., Joseph, H., Kahn, S. E., Kaskalla, R. S., Katz, P., Katz, R., Katzir, N., Kavena, K., Keasler, L., Kellum, T., Kelly, S. M., Kelly-Dinham, K., Kennedy, B. M., Kerr, M., Kessler, D., Khare-Ranade, P., Killeen, A., King, C., Kirby, L., Kirkman, M. S., Kitabchi, A. E., Kloiber, S., Knopp, R. H., Knowler, W. C., Kobus, K. M., Kocal, M., Koenning, G., Kolinjivadi, P., Krakoff, J., Kramer, M. K., Kriska, A. M., Kuenster, N. D., Kula, L. M., Kurland, J., Lachin, J. M., Laferrere, B., Lagarda, M., Lambert, L., Lambeth, H., Lamkin, M., Lara, O., Larkin, M., Larreal, C., Larsen, D., Larsen, M. D., Latimer, R. W., Lawrence, D., Lawton, K. E., Leandre, F., Ledbury, S., Lee, J. E., Lee, C., Lenz, D., Leon, L., Leos, D., Levatan, C., Levy, E., Li, Y., Liberoni, R., Lichtermann, L. C., Lindsay, M., Lipkin, E. W., Lockett, M., Loman, K., Longchamp, N., Lorenzo, C., Lou, P., Love Burkott, H., Lovejoy, J. C., Lowe, A., Luchsinger, J. A., Lukin, J., Lyman, M., Ma, Y., Magee, M., Magpuri, P., Malloy, M. A., Manjoo, Q., Manly, J., Manus, C., Marcovina, S., Marr, M., Marrero, D. G., Martinez, A., Martinez, H., Mather, K. J., Mathioudakis, N., Matulik, M. J., Mau, M. K., Mayer-Davis, E., McAtee, G., McCabe, C., McDaniel, K., McKitrick, C., McLymont, V., McMaster, A., McNabb, W., McPherson, D., Melancon, L. E., Melish, J. S., Mendez, J., Mendoza, J., Metzger, B. E., Michaels, S., Middelbeek, R. J. W., Middendorf, J., Mikami, K., Miller, M., Mills, M., Mohideen, P., Molitch, M. E., Montez, M. G., Montgomery, B. K., Moran, R. R., Morgan, T., Morgan-Taggart, I., Morris, L. H., Mosley, H., Mucik, P., Mudaliar, S., Mugford, M., Mullen, M., Mundra, R., Munshi, M., Murillo, A., Muro, C., Murphy, M. E., Myers, D., Nair, A. K., Nash, P. V., Nashboo, Y., Natewa, C., Nathan, D. M., Navy, C., Neira, N., Nelson, J. A., Ngo, K., Nicosia, M., Nilan, T., Noel, A., Nyenwe, E. A., O'Brien, M., O'Kelly Phillips, E., O'Leary, D., O'Neal, K., Odom, S. K., Oktaei, H., Oldmixon, C. F., Olefsky, J. M., Orchard, T., Orlosky, R., Otto, A., Pak, J., Pal, C., Palermo, L., Pan, J., Pan, Q., Park, J., Parkes, K., Passaro, M., Patel, A., Pemberton, N., Pena, M., Penn, S. C., Pepe, C., Percy, C. A., Perreault, L., Perry, A., Perry, R. U., Pettigrew, J., Pinner, K. L., Piromalli, C., Pi-Sunyer, F. X., Pitts, T., Poirier, C. S., Poirier, S., Polczynski, E., Pollin, T. I., Polonsky, K. S., Polonsky, W., Pompi, D., Porter, B. D., Poulos, A., Powell, D., Price, D. W., Prince, M. J., Prineas, R. J., Putenney, P., Quitingon, M., Rainville, R., Rapoport, H., Rassam, A., Ratner, R. E., Rautaharju, P., Rautaharju, F., Raymond, E., Reamer, S., Regensteiner, J. G., Reidy, M., Reimers, J., Reinhart, R., Reusing, J., Ricks, H., Ripley, V., Roach, P. J., Rochon, J., Rockette-Wagner, B., Rooney, E. S., Rosario Araneta, M., Roston, S., Roumain, J., Rowe, P., Rowland, N. D., Rowse, D., Roy, R. J., Rubin, R. R., Rubinchik, S., Rubinstein, D., Rubtchinsky, S., Ruiz, R., Rutledge, L. M. K., Ryan, D. H., Ryder, L., Saab, P., Saad, M. F., Salazar, M., Samuels, A., Sanford, D. A., Sangster, S., Sanguily, J., Sansoucy, J., Santiago, J. V., Santiago, A., Sapozhnikova, A., Sarkin, A. J., Saudek, C. D., Schade, D. S., Scheindlin, J., Schinleber, P. A., Schroeder, E. B., Schwartz, A., Schweizer, D., Seagle, H., Seely, E. W., Semenske, A. R., Semler, L., Senter, W., Sewenemewa, J., Shamoon, H., Shapiro, S., Shaw, R., Sherif, H., Sherman, A. R., Shields, T., Shuldiner, A. R., Silverman, A., Simmons, M., Simonson, D., Smart, M., Smith, K. G., Smith, L. L., Smith, K. A., Smith, C. M., Smith, F., Smith, C. M., Smith, J., Smith, M., Smith, C. F., Soberman, J. E., Soliman, E. Z., Solomon, C. G., Sosa, A., Spandorfer, J., Spellman, J., Spencer, C., Srikanthan, P., St Amant, J. A., Stamm, E., Steinke, S. C., Stephens, S., Stevens, C., Stewart, K. J., Stich, T., Stimpson, C., Strylewicz, G., Sullivan, E., Swift, M., Swift, K., Szerdi Janesch, S., Tadros, S., Taylor, T., Taylor, L., Taylor, L., Temple, K. A., Temprosa, M., Testaverde, L., Thangthaeng, N., Thomas, L., Thomas, C. C., Thomas, A., Tobian, J., Tomuta, N., Tonemah, D., Torio-Hurley, J., Trandafirescu, G., Trence, D., Truong, J., Tsai, E. C., Tseng, B., Tulley, R. T., Turgeon, H., Utsey, E., Uwaifo, G., Van, G. E. H., VanDorsten, B., Vargo, P., Veciana, B., Vejvoda, K., Venditti, E. M., Vicknair, P. C., Villarreal, V., Violino, E., Viscovich, K. A., Walker, E. A., Walker, T., Walker-Murray, F., Wallia, A., Warram, J., Waters, D., Watson, S., Watson, P. G., Watson, K., Weinzierl, V., Wells-Thayer, D., Wernimont, C., Wheeler, M. L., White, N. H., Whittington, T., Wiggins, R., Wildman, W., Williams, K. V., Williams, R., Williams-Cleaves, B., Williamson, P., Williamson, D., Wilson, T., Wilson, C., Wing, R. R., Wylie-Rosett, J., Xapthalamous, K., Yamamoto, R. E., Yazzie, M., Youssef, G., Zachwieja, J. J., Zhang, P., Zhang, Z., Zimmerman, E., & Zonszein, J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- VA Eastern Colorado Health Care System (US)
- University of New Mexico Health Sciences Center (US)
- ORCID
- Kalyani, Rita R
- Kim, Catherine
- Raghavan, Sridharan
- Shah, Vallabh O
- Ackermann, Ronald T.
- Allison, David B.
- Altshuler, David
- Barrett-Connor, Elizabeth
- Budoff, Matthew
- Champagne, Catherine M.
- Edelman, Steven V.
- Harden, Maegan
- Hivert, Marie-France
- Marrero, David G.
- Mather, Kieren J.
- Mathioudakis, Nestoras
- Olefsky, Jerrold M.
- Prince, Melvin J.
- Schwartz, Ann
- Uwaifo, Gabriel
- Wing, Rena R.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2025-06
- Volume
- 13
- Issue
- 6
- Pages
- 469-481
- ISSN
- 2213-8587 (ISSN-L)
- PMC
- PMC12414453
- OpenAlex
- W4409875193
- Cited by
- 39
- References
- 27
- Citations by year
- 2026: 27 · 2025: 12
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Update notices
- erratum (2025-06-01)
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 172 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Diabetes & Endocrinology (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK048397, U01 DK048411, U01 DK048434, U01 DK048443, U01 DK048407, U01 DK048381, U01 DK048485, U01 DK048387, U01 DK048412, U01 DK048349, U01 DK048377, U01 DK048413, U01 DK048489, U01 DK048468, U01 DK048514, U01 DK048406, U01 DK048375, U01 DK048380, U01 DK048404, U01 DK048339, U01 DK048400, U01 DK048437)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes incidence, prediabetes, intensive lifestyle intervention, metformin, long-term treatment outcomes, heterogeneous effects, subgroup analysis, diabetes prevention, booster intervention, diabetes risk factors, diabetes remission, remission maintenance, remission duration
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Life Style, Male, Metformin, Middle Aged, Prediabetic State, United States, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. https://app.cochat.ai/papers/10.1016/s2213-8587(25)00022-1
- The paper
- Knowler, W. C., Doherty, L., Edelstein, S. L., Bennett, P. H., Dabelea, D., Hoskin, M., Kahn, S. E., Kalyani, R. R., Kim, C., Pi-Sunyer, F. X., Raghavan, S., Shah, V. O., Temprosa, M., Venditti, E. M., Nathan, D. M., Abbas, C., Abbott, K., Abebe, S., Ackermann, R. T., . . . Zonszein, J. (2025). Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(25)00022-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.